Your browser doesn't support javascript.
loading
Handling of Germline Findings in Clinical Comprehensive Cancer Genomic Profiling.
Okazawa-Sakai, Mika; Yamamoto, Yasuko; Futagawa, Mashu; Okamura, Miki; Miyawaki, Satoko; Nishina, Tomohiro; Takehara, Kazuhiro; Kozuki, Toshiyuki; Tomida, Shuta; Hyodo, Ichinosuke; Ohsumi, Shozo; Hirasawa, Akira.
Afiliación
  • Okazawa-Sakai M; Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
  • Yamamoto Y; Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center.
  • Futagawa M; Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center.
  • Okamura M; Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center.
  • Miyawaki S; Department of Hereditary Tumors, National Hospital Organization Shikoku Cancer Center.
  • Nishina T; Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
  • Takehara K; Department of Hereditary Tumors, National Hospital Organization Shikoku Cancer Center.
  • Kozuki T; Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center.
  • Tomida S; Department of Hereditary Tumors, National Hospital Organization Shikoku Cancer Center.
  • Hyodo I; Department of Cancer Genomic Medicine, National Hospital Organization Shikoku Cancer Center.
  • Ohsumi S; Department of Hereditary Tumors, National Hospital Organization Shikoku Cancer Center.
  • Hirasawa A; Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center.
Acta Med Okayama ; 76(6): 673-678, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36549769
ABSTRACT
Patients found to have presumed germline pathogenic variants (PGPVs) during comprehensive genomic profiling (CGP) require genetic counseling (GC) referrals. We retrospectively investigated the outcomes of patients with PGPVs. Among 159 patients who underwent CGP, we recommended GC for the 16 patients with PGPVs (3 with [FG group] and 13 without [G Group] a family/personal history of hereditary cancer) as well as for the 8 patients with no PGPVs, but a history (F group); 2 (67%), 5 (38%), and 3 (38%) patients received GC in the FG, G, and F groups, respectively. Germline testing results were positive in 1 and 2 patients of the FG and G groups, respectively. Among the patients recommended for GC, 58% did not receive GC due to lack of interest, poor performance status, or death. CGP contributes to the identification of germline variants in patients without a history of hereditary cancer. However, the proportion of patients who undergo GC should be improved.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Neoplasias Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Acta Med Okayama Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Neoplasias Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Acta Med Okayama Año: 2022 Tipo del documento: Article